Caplin Point Laboratories Limited

Caplin Point Laboratories delivered robust financial results for FY25, with total revenue reaching ₹2,034 crores, marking a 15% year-on-year growth. Profit After Tax (PAT) grew by 17% to ₹541 crores, achieving an all-time high PAT margin of 26.6%. The company also reported an all-time high gross margin of 60.2% and a PBT margin of 33.3%, reflecting strong operational efficiency and product mix.

Caplin Steriles, the US-focused entity, demonstrated significant growth, with revenues increasing 5x over the last five years to ₹366 crores in FY25, generating an EBITDA of ₹102 crores. While the US operating revenue grew by 13% in FY25, management emphasized a strategy of high-quality, sustainable growth over aggressive top-line chasing. The target of achieving a $100 million run rate for Caplin Steriles is now expected to be realized 18 months later than initially projected, prioritizing profitability and compliance.

The company made substantial progress in its product pipeline and market expansion efforts. In Mexico, 30 products have been filed, with 13 already approved, and over 60 more products are slated for filing in the next 12 months. Caplin Point also received its first insulin product approval in Central America and plans to file more doses in other Latin American countries. The Pondicherry facility (CP-1) is set to launch a unique double-chamber pre-filled syringe in Latin American markets, and 95 products have been registered in Chile, contributing to increased sales and profit.

Caplin Point has completed API R&D for 85 products, including 51 general injectables and 34 Onco injectables/OSD. The strategy involves initially manufacturing these APIs in a Chinese facility to leverage economies of scale, with plans for later manufacturing in India for captive consumption. One API facility is expected to be completed in the next 2-3 months, supporting backward integration and cost control.

The company maintains a strong and debt-free balance sheet, with management stating they are not a debt-driven company. Liquid assets stood at ₹2,150 crores, including ₹1,180 crores in cash and cash equivalents. Over the last five years, ₹700 crores have been invested in fixed assets, funded entirely through internal accruals. This conservative capital allocation approach supports organic growth and potential meaningful acquisitions in the future.

Management anticipates the next 18-24 months to be a 'transitionary period' as new initiatives in Latin America (Mexico, Brazil), Oncology, and the US front end mature. They are confident that a 'second revenue stream' will perform 'extremely well in three years from now.' The company is also implementing a cost control tracker to enhance discipline and monitor financial activities, aiming for a 25-30% cost reduction at the Pondicherry factory.